Skip to main content
. 2022 Oct 24;13:1009864. doi: 10.3389/fimmu.2022.1009864

Table 1.

Complement-based therapies currently under trial for MN.

Name of drug Target Phase of development
BCX9930 Factor D Phase II
(NCT05162066)
Eculizumab C5 Aborted
Iptacopan (LNP023) Factor B Phase II
(NCT04154787)
Narsoplimab (OMS721) MASP2 Phase II
(NCT02682407)
Pegcetacoplan (APL-2) C3, C3b Aborted